The antibiotic has been developed by the Biotechnology Industry Research Assistance Council (BIRAC),” and is one of the first to be developed globally in its class in 30 years.

The antibiotic will be available under the trade name, “Miqnaf”, and is aimed to treat community-acquired bacterial pneumonia.

The drug would be prescribed as a three-day regimen, and has been found to be 10 times more effective and safer than the current options.

The antibiotic has been observed to cause minimal GI side effects, no significant drug interactions and has not been shown to be affected by food consumption.

Currently, the approval from Central Drugs Standard Control Organization is awaited before its public use.

This step underscores the role of innovation and collaboration in tackling public health concerns.